The eya tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tadjuidje, Emmanuel ^a   Wang, Tim Sen ^a   Pandey, Ram Naresh ^a   Sumanas, Saulius ^a   Lang, Richard A ^a,c   Hegde, Rashmi S ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZARONE; BENZBROMARONE; EYES ABSENTS 2 PROTEIN; EYES ABSENTS 3 PROTEIN; EYES ABSENTS PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENZYME INHIBITOR; EYA1 PROTEIN, HUMAN; EYA2 PROTEIN, HUMAN; EYA3 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; URICOSURIC AGENT;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; CAPILLARY TUBE; CELL MIGRATION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; ZEBRA FISH; ANIMAL; AORTA; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM;

ANIMALS; AORTA; BENZBROMARONE; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; NEOVASCULARIZATION, PHYSIOLOGIC; NUCLEAR PROTEINS; PROTEIN TYROSINE PHOSPHATASES; RNA INTERFERENCE; URICOSURIC AGENTS; ZEBRAFISH;

EID: 84860136353     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034806     Document Type: Article

References (50)

1. Okabe Y, Sano T, Nagata S, (2009) Regulation of the innate immune response by threonine-phosphatase of Eyes absent. Nature 460: 520-524.
2. Rayapureddi JP, Kattamuri C, Steinmetz BD, Frankfort BJ, Ostrin EJ, et al. (2003) Eyes absent represents a class of protein tyrosine phosphatases. Nature 426: 295-298.
3. Tootle TL, Silver SJ, Davies EL, Newman V, Latek RR, et al. (2003) The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature 426: 299-302.
4. Li X, Oghi KA, Zhang J, Krones A, Bush KT, et al. (2003) Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426: 247-254.
5. Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, et al. (2010) The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene.
6. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, et al. (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458: 591-596.
7. Krishnan N, Jeong DG, Jung SK, Ryu SE, Xiao A, et al. (2009) Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent. J Biol Chem.
8. Xu PX, Adams J, Peters H, Brown MC, Heaney S, et al. (1999) Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet 23: 113-117.
9. Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, et al. (1997) Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. Hum Mol Genet 6: 2247-2255.
10. Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, et al. (1997) A human homologue of the Drosophila eyes absent gene underlies branchio- oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet 15: 157-164.
11. Azuma N, Hirakiyama A, Inoue T, Asaka A, Yamada M, (2000) Mutations of a human homologue of the Drosophila eyes absent gene (EYA1) detected in patients with congenital cataracts and ocular anterior segment anomalies. Hum Mol Genet 9: 363-366.
12. Wayne S, Robertson NG, DeClau F, Chen N, Verhoeven K, et al. (2001) Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus. Hum Mol Genet 10: 195-200.
13. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL, (2011) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene.
14. Zhang L, Yang N, Huang J, Buckanovich RJ, Liang S, et al. (2005) Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 65: 925-932.
15. Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, et al. (2010) Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene 29: 368-379.
16. Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, et al. (2010) The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 29: 3715-3722.
17. Schonberger J, Wang L, Shin JT, Kim SD, Depreux FF, et al. (2005) Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet.
18. Shimasaki N, Watanabe K, Hara M, Kosaki K, (2004) EYA1 mutation in a newborn female presenting with cardiofacial syndrome. Pediatric cardiology 25: 411-413.
19. Soker T, Dalke C, Puk O, Floss T, Becker L, et al. (2008) Pleiotropic effects in Eya3 knockout mice. BMC Dev Biol 8: 118.
20. Guo C, Sun Y, Zhou B, Adam RM, Li X, et al. (2011) A Tbx1-Six1/Eya1-Fgf8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. The Journal of clinical investigation 121: 1585-1595.
21. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, et al. (2004) Protein tyrosine phosphatases in the human genome. Cell 117: 699-711.
22. Rayapureddi JP, Kattamuri C, Chan FH, Hegde RS, (2005) Characterization of a plant, tyrosine-specific phosphatase of the aspartyl class. Biochemistry 44: 751-758.
23. El-Hashash AH, Al Alam D, Turcatel G, Bellusci S, Warburton D, (2011) Eyes absent 1 (Eya1) is a critical coordinator of epithelial, mesenchymal and vascular morphogenesis in the mammalian lung. Dev Biol 350: 112-126.
24. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, et al. (2000) The molecular basis of lung morphogenesis. Mech Dev 92: 55-81.
25. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
26. McGovern SL, Helfand BT, Feng B, Shoichet BK, (2003) A specific mechanism of nonspecific inhibition. Journal of medicinal chemistry 46: 4265-4272.
27. Ryan AJ, Gray NM, Lowe PN, Chung CW, (2003) Effect of detergent on "promiscuous" inhibitors. Journal of medicinal chemistry 46: 3448-3451.
28. Ikeda K, Watanabe Y, Ohto H, Kawakami K, (2002) Molecular Interaction and Synergistic Activation of a Promoter by Six, Eya, and Dach Proteins Mediated through CREB Binding Protein. Mol Cell Biol 22: 6759-6766.
29. Jung SK, Jeong DG, Chung SJ, Kim JH, Park BC, et al. (2009) Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor. FASEB J.
30. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201.
31. Melo F, Devos D, Depiereux E, Feytmans E, (1997) ANOLEA: a www server to assess protein structures. Proc Int Conf Intell Syst Mol Biol 5: 187-190.
32. Abagyan R, Totrov M, Kuznetsov D, (2004) ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem 15: 488-506.
33. Gerhardt H, Betsholtz C, (2005) How do endothelial cells orientate? EXS pp. 3-15.
34. Langheinrich U, (2003) Zebrafish: a new model on the pharmaceutical catwalk. BioEssays: news and reviews in molecular, cellular and developmental biology 25: 904-912.
35. Staton CA, Reed MW, Brown NJ, (2009) A critical analysis of current in vitro and in vivo angiogenesis assays. International journal of experimental pathology 90: 195-221.
36. Jin SW, Beis D, Mitchell T, Chen JN, Stainier DY, (2005) Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development 132: 5199-5209.
37. Sapieha P, Joyal JS, Rivera JC, Kermorvant-Duchemin E, Sennlaub F, et al. (2010) Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. The Journal of clinical investigation 120: 3022-3032.
38. Economopoulou M, Langer HF, Celeste A, Orlova VV, Choi EY, et al. (2009) Histone H2AX is integral to hypoxia-driven neovascularization. Nature medicine 15: 553-558.
39. Xiao A, Li H, Shechter D, Ahn SH, Fabrizio LA, et al. (2009) WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature 457: 57-62.
40. Wrobel J, Sredy J, Moxham C, Dietrich A, Li Z, et al. (1999) PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[β]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. Journal of medicinal chemistry 42: 3199-3202.
41. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, et al. (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nature structural & molecular biology 11: 730-737.
42. Rayapureddi JP, Hegde RS, (2006) Branchio-oto-renal syndrome associated mutations in Eyes Absent 1 result in loss of phosphatase activity. FEBS Lett 580: 3853-3859.
43. Park H, Jung SK, Yu KR, Kim JH, Kim YS, et al. (2011) Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties. Chemical biology & drug design 78: 642-650.
44. Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, et al. (2011) Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology 16: 156-162.
45. Walter-Sack I, de Vries JX, Ittensohn A, Weber E, (1990) Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. European journal of clinical pharmacology 39: 577-581.
46. Andreu I, Mayorga C, Miranda MA, (2009) Metabolomics in drug intolerance. Current drug metabolism 10: 947-955.
47. Lee MH, Graham GG, Williams KM, Day RO, (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug safety: an international journal of medical toxicology and drug experience 31: 643-665.
48. Tran JC, Zamdborg L, Ahlf DR, Lee JE, Catherman AD, et al. (2011) Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature.
49. Aplin AC, Fogel E, Zorzi P, Nicosia RF, (2008) The aortic ring model of angiogenesis. Methods Enzymol 443: 119-136.
50. Reed MJ, Damodarasamy M, Vernon RB, (2011) Angiogenesis In Vitro Utilizing Murine Vascular Explants in Miniaturized 3-Dimensional Collagen Gels. The open circulation & vascular journal pp. 12-17.